MREO saw its Momentum Indicator move below the 0 level on January 10, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned negative. In of the 91 cases, the stock moved further down in the following days. The odds of a decline are at .
The Moving Average Convergence Divergence Histogram (MACD) for MREO turned negative on January 14, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .
MREO moved below its 50-day moving average on January 10, 2025 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for MREO moved below the 200-day moving average on January 08, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MREO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The RSI Indicator entered the oversold zone -- be on the watch for MREO's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MREO advanced for three days, in of 245 cases, the price rose further within the following month. The odds of a continued upward trend are .
MREO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.116) is normal, around the industry mean (14.746). P/E Ratio (0.000) is within average values for comparable stocks, (87.786). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.852). MREO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (416.667) is also within normal values, averaging (263.573).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. MREO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
a company, which engages in therapeutics that aim to improve outcomes for patients with osteogenesis imperfecta, alpha-1 antitrypsin deficiency, hypogonadotropic hypogonadism in obese men, and acute exacerbations of chronic obstructive pulmonary disease
Industry Biotechnology
A.I.dvisor indicates that over the last year, MREO has been loosely correlated with URGN. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if MREO jumps, then URGN could also see price increases.
Ticker / NAME | Correlation To MREO | 1D Price Change % | ||
---|---|---|---|---|
MREO | 100% | -1.38% | ||
URGN - MREO | 36% Loosely correlated | -2.38% | ||
TERN - MREO | 35% Loosely correlated | -1.56% | ||
INZY - MREO | 32% Poorly correlated | N/A | ||
ARCT - MREO | 30% Poorly correlated | -1.29% | ||
ACLX - MREO | 30% Poorly correlated | -0.79% | ||
More |